News & Updates

Women with a dietary pattern contributing to hyperinsulinaemia and insulin resistance appear to be at increased risk of breast cancer, particularly estrogen-receptor (ER)-negative and human epidermal growth factor receptor 2 (HER2)-enriched tumours, reveals a study.

The second-generation BTK* inhibitor zanubrutinib was superior to the standard-of-care ibrutinib in improving progression-free survival (PFS) among patients with relapsed/refractory chronic lymphocytic leukaemia (R/R CLL) or small lymphocytic lymphoma (SLL), according to results of the phase III ALPINE trial presented at ASH 2022.

Adalimumab for the treatment of hidradenitis suppurativa appears to be less effective in patients with obesity, a study has found.

Circulating homocysteine and folate concentrations appear to play a significant role in the development of nonalcoholic fatty liver disease (NAFLD), a study has shown.

YLB113, a biosimilar of the reference product etanercept, appears to be safe for long-term treatment of patients with rheumatoid arthritis, with efficacy sustained for up to 96 weeks, according to a study. Notably, the biosimilar is associated with fewer cases of injection-site reactions and injection-site erythema compared with the reference.

Ritlecitinib and brepocitinib as induction therapies for ulcerative colitis (UC) appear to be more effective than placebo while having an acceptable short-term safety profile, according to the results of a phase IIb study.